MedTrace Logo

Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease

NCT07152977 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2025-09-03

No results posted yet for this study

Summary

The presence of ano-perineal lesions (APL) in Crohn's disease is common and represents a major burden for the patient. More than one-third of patients with Crohn's disease will develop at least one ano-perineal lesion during the course of their disease. The cumulative incidence of APL is approximately 30% at 10 years and 43% at 20 years, regardless of the type of APL.

The appearance of ano-perineal lesions represents an important phase in the progression of Crohn's disease, but they have been little studied to date. There is little consensus regarding their overall management. Indeed, their management is difficult due to their destructive and recurrent nature, and their significant impact on patients' quality of life, continence, and sexuality is significant. The presence of ano-perineal lesions at the time of diagnosis, especially in young patients, is a poor prognostic factor.

Conditions

  • Anoperineal Lesions
  • Crohn's Disease Relapse

Interventions

OTHER

Radiological evolution of ano-perineal lesions by MRI

Patients selected retrospectively will have benefited from an MRI at diagnosis and a control MRI during follow-up. They will be selected during a follow-up consultation or a biotherapy injection in a day hospital. Patients selected consecutively are monitored at the Rouen University Hospital for perineal Cohn's disease, treated with Biotherapy: Infliximab, Adalimumab, Ustekinumab, Vedolizumab.

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2024-01-31
Completion
2024-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07152977 on ClinicalTrials.gov